IQ-AI Regulatory News (IQAI)

IQ-AI Ltd

("IQ-AI" or the "Company")

Update - IB Stroke™ 

In November 2019, IQ-AI announced the addition of IB Stroke to its product roadmap. As a logical extension of its current portfolio of proven neuro products, IB Stroke has the advantage of leveraging existing FDA cleared and CE marked algorithms to rapidly generate information commonly used in the diagnosis of stroke in patients. The team at IQ-AI's subsidiary, Imagining Biometrics ("IB") is pleased to announce that the development of IB Stroke is on track. In addition, a subcommittee of the USA Jumpstarting Brain Tumour Drug Development Coalition has recently recommended that the quantitative perfusion capability, exclusive to IB, provides a singular foundation upon which to build IB Stroke and is now the consensus recommended standard for the National Clinical Trials Network.

The technology will first be made available as part of a streamlined workflow within IB Rad Tech and is on target to be released in early Q4. IB Rad Tech harnesses the power of the individual software modules and combines them into customised and efficient workflows. Along with IB Neuro, IB Diffusion and IB Delta Suite will also be part of the overall IB Stroke workflow within IB Rad Tech. As the final stages of software development are completed, IB Stroke will begin software validation testing as required for regulatory compliance and commercial distribution. IB recently passed their annual ISO 13485:2016 recertification audit; an international quality standard and pre-requisite for European distribution.

IB is pleased to announce the appointment of Dr. Vasileios Κ. Katsaros, MD, PhD to the IB team, as key opinion leader and collaborator. Dr. Katsaros holds positions including Consultant Radiologist - Neuroradiologist, Department of Advanced Imaging Modalities (MRI Unit) of General Anti-Cancer and Oncological Hospital of Athens "St. Savvas" and Research Affiliate in the Departments of Neurosurgery and Neurology, National and Kapodistrian University of Athens and the Department of Neuroradiology, University College of London (UCL).

"I have been using IB Software for several years and I am highly confident in the underlying science of their products," said Dr. Katsaros. "The streamlined workflows available in IB Rad Tech simplify and automate the processing of sophisticated maps and I am pleased to offer feedback for the IB Stroke workflow," added Dr. Katsaros.

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

ABOUT Imaging Biometrics, LLC

Imaging Biometrics®, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.